ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 12, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Company maintains healthy operating position with US$78.1 million in cash, cash equivalents and short-term investments as of June 30, 2022, runway through late 2023- Three abstracts showcasing new...
ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress
August 11, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis
June 07, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, June 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: ‘Dialogues With International Thought Leaders in Dermatology’
June 06, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, June 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 31, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, May 31, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting
May 20, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, May 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, May 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual Meeting
May 10, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, May 10, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
April 27, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) progressing, multiple sites enrolling; topline data expected in the first half of 2023Alex Kaoukhov, MD, appointed as...
ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022
April 06, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...